

TREATMENT ALGORITHMS IN LUMINAL BREAST CANCER THERAPY: LEARNING FROM THE PRESENT TO DESIGN THE FUTURE

MEETING

MILAN, MAY 23RD - 24TH, 2024

COURSE DIRECTORS

Carmen Criscitiello

Claudio Vernieri



ACCADEMIA NAZIONALE DI MEDICINA

SEZIONE DI ONCOLOGIA

WITH THE ENDORSEMENT OF



www.accmed.org

10 CME CREDITS

OBJECTIVES

The main objective of this meeting is to involve young and talented preclinical and clinical scientists in a debate about the most promising directions of present and future independent research on early stage or advanced luminal breast cancer. The Congress will be focused on new experimental approaches that could be implemented in the clinic, such as metabolic interventions, or the use of algorithms of artificial intelligence to guide the choice between different CDK4/6 inhibitors in first-line treatment of advanced disease, or to personalize therapeutic sequences after progression to first line therapy.

ADDRESSED TO

Medical oncologists, pathologists, radiologists. Biologists, pharmacists.

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) assigns to the CME activity (**31-413439**): **10 CME credits**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialization and highly specialized activity. Rare disease.

The credit certification is subject to:

- professions/specializations should correspond to those which have been accredited for CME;
- attendance at the 90% of the meeting;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 1 attempt admitted. The test and the meeting evaluation form must be completed within 3 days from the end of the event.

PROGRAM

THURSDAY, MAY 23

10.30 *Registration*

11.15 **Opening**

Carmen Criscitiello, Claudio Vernieri

SESSION 1.

ROLE OF CDK4/6 INHIBITORS IN EARLY BREAST CANCER

Chairs: Carmen Criscitiello, Carmine De Angelis

11.30 **CDK4/6i as a new standard in the adjuvant treatment for HR+/HER2- early BC patients**

Luca Licata

11.50 **Neoadjuvant CDK4/6i in combination with endocrine therapy: how much are we far from clinical implementation?**

Antonio Marra

12.10 **Impact of CDK4/6i on quality of life of breast cancer patients' quality of life**

Gaia Griguolo

12.30 **Economic and social impact of early BC treatment on Health Care Systems**

Dario Trapani

12.50 **Discussion**

13.10 *Light Lunch*

**SESSION 2.
CDK4/6 INHIBITORS FOR THE TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER**

Chairs: Maria Vittoria Dieci, Matteo Lambertini

14.10 **CDK4/6i as first-line treatment**

Beatrice Taurelli Salimbeni

14.30 **Real world data on CDK4/6i: which their reliance in clinical choices?**

Angela Toss

14.50 **CDK4/6i beyond CDK4/6i: is there a role in the adjuvant CDK4/6i era?**

Claudia Omarini

15.10 **Discussion**
Working groups for the discussion of potential collaboration studies

Each of 5 working groups, with a tutor, discusses and drafts a collaborative study focused on CDK4/6i in early stage or advanced HR+/HER2- BC

16.45 Public presentation and discussion of each project (10 min each)

17.35 **Review of day 1 and conclusions**

Carmen Criscitiello, Claudio Vernieri

18.00 **Adjourn**

FRIDAY, MAY 24

SESSION 3. CDK4/6 INHIBITORS: DEEP UNDERSTANDING OF MOLECULAR MECHANISMS TO DESIGN NEW TREATMENT COMBINATIONS

Chair: Claudio Vernieri

- 9.00 **Molecular mechanism of resistance to CDK4/6i: the UNDERSTAND study**
Andrea Vingiani
- 9.20 **Combining the inhibition of CDK4/6i with PI3K/AKT/mTORC pathway: from preclinical evidence to clinical trials**
Gianpiero Rizzo
- 9.40 **CDK4/6i immunomodulation to sensitize breast tumors to immune checkpoint inhibition**
Andrea Botticelli

- 10.00 **Discussion**
- 10.20 **Lecture: Role of CDK4/6i in ER-low BC**
Maria Vittoria Dieci

10.40 *Coffee Break*

SESSION 4. TARGETIN CANCER METABOLISM TO BOOST CDK4/6 INHIBITOR TREATMENTS EFFICACY

Chairs: Francesca Ligorio,
Claudio Vernieri

- 11.00 **Combining CDK4/6i with metabolic interventions: a new way to HR+/HER2- BC cure?**
Irene Caffa
- 11.20 **Uncovering new metabolic strategies to reverse resistance to CDK4/6 inhibitors in HR+/HER2- BC**
Marzia Santamaria

- 11.40 **Combining CDK4/6i with fasting mimicking diet: preliminary clinical evidence**
Francesca Ligorio

12.00 **Discussion**

12.15 *Light Lunch*

SESSION 5. DRAWING THE IDEAL CANDIDATE FOR POST- CDK4/6 INHIBITOR TREATMENTS

Chairs: Carmen Criscitiello,
Claudio Vernieri

- 13.15 **Available treatment options upon progression to CDK4/6 inhibitors**
Lorenzo Gerratana
- 13.35 **Future treatment strategies for patients progressing to CDK4/6 inhibitors**
Flavia Jacobs

- 13.55 **Real world data on post-CDK4/6 inhibitor treatments**
Giulia Viale

- 14.15 **Building a trustworthy AI-based model to predict CDK4/6i efficacy: multiomic analysis from the PALMARES2 study + radiomica**
Leonardo Provenzano

14.35 **Discussion**

- 15.00 **Take-home messages**
Carmen Criscitiello,
Claudio Vernieri

15.15 **Adjourn**

COURSE DIRECTORS

Carmen Criscitiello

Divisione di Oncologia Medica
IEO Istituto Europeo di Oncologia
Milano

Claudio Vernieri

Unimi - Università degli Studi
Dipartimento di Oncologia Medica
Fondazione IRCCS Istituto
Nazionale dei Tumori
IFOM ETS, Istituto di Oncologia
Molecolare
Milano

FACULTY

Andrea Botticelli, Roma

Irene Caffa, Genova

Carmine De Angelis, Napoli

Maria Vittoria Dieci, Padova

Lorenzo Gerratana, Aviano (PN)

Gaia Griguolo, Padova

Flavia Jacobs, Rozzano (MI)

Matteo Lambertini, Genova

Luca Licata, Milano

Francesca Ligorio, Milano

Antonio Marra, Milano

Claudia Omarini, Modena

Leonardo Provenzano, Milano

Gianpiero Rizzo, Pavia

Marzia Santamaria, Milano

Beatrice Taurelli Salimbeni, Milano

Angela Toss, Modena

Dario Trapani, Milano

Giulia Viale, Milano

Andrea Vingiani, Milano

REGISTRATION

Participation in the course is free, places available are limited. It is possible to register online at: <https://fad.accmed.org/course/info.php?id=1525> by **19 may 2024**. Registration will be accepted in the chronological order of arrival and will be confirmed by e-mail.

MEETING VENUE

AULA MAGNA

IRCCS Fondazione Istituto Nazionale
Tumori
Via Venezian, 1
Milano

ORGANIZER

ACCADEMIA NAZIONALE DI MEDICINA

General Director: Stefania Ledda
Via Martin Piaggio 17/6
16122 Genova



Information:

fad.acamed.org
Ph. 010 83794239
Mob: 335 7112604

LOGISTICS AND TECHNOLOGICAL SERVICES

Forum Service

Via Martin Piaggio, 17/7
16122 Genova
www.forumservice.net

SUPPORTED BY UNRESTRICTED EDUCATIONAL GRANTS FROM

PLATINUM SPONSOR



BRONZE SPONSOR



CONTRIBUTOR

